Investors Archive & Merger Documents
Brought together here for easy access, explore all the press releases, presentations, reports, calls and webcasts DSM has published in the last decade on its financial results, Capital Markets
See more about DSM's former share information
See DSM's EGM information
We fervently believe in doing business the right way, from our Managing and Supervisory Boards, to our Code of Business Ethics, to our positions on key industry issues.
Firmenich International SA was founded in 1895 in Geneva, Switzerland, and has been a private, family-owned company for 125 years. In 2023, Firmenich merged with DSM and became dsm-firmenich. You can still acess former investor relations information of Firmenich here.
dsm-firmenich completes voluntary cash offer for DSM shares
12.02.2024
dsm-firmenichmakes voluntary cash offer for DSM shares
08.01.2024
DSM-Firmenich AG announces the successful placement of c. 6.7 million existing DSM-Firmenich ordinary shares through an accelerated bookbuild offering for a total amount of €733 million
25.05.2023
DSM-Firmenich AG launches the sale of up to c. 6.7 million existing DSM-Firmenich ordinaryshares through an accelerated bookbuild offering
24.05.2023
Final results of the exchange offer: 96.1% of DSM ordinary shares tendered
01.05.2023
dsm-firmenich first day of trading on Euronext Amsterdam
18.04.2023
Exchange offer declared unconditional
17.04.2023
Second supplement to offering circular
06.04.2023
DSM and Firmenich have obtained all competition clearances
04.04.2023
Acceptance period second extension announcement
31.03.2023
DSM and Firmenich have obtained competition clearance from the European Commission
23.02.2023
Acceptance period extension announcement
23.01.2023
DSM announces results of EGM
23.01.2023
Exchange offer & EGM announcement
22.11.2022
dsm-firmenich update on public exchange offer process
28.06.2022
DSM and Firmenich confirm leadership team
13.06.2022
Merger announcement (EN)
31.05.2022
Merger announcement (FR)
31.05.2022
Merger announcement (DE)
31.05.2022
Merger announcement (NL)
31.05.2022
EGM presentation – 23 Jan
23.01.2023
Investor presentation - 13 June (EN)
13.06.2022
Investor call transcript - 31 May (EN)
08.06.2022
Second supplement to the offering circular
06.04.2023
Supplement to the offering circular
03.03.2023
Offering circular
22.11.2022
U.S. investor letter
Firmenich Q1 2023 trading update
22.11.2022
Firmenich annual report for the financial year ended 2022
Firmenich interim consolidated financial statements for the six months ended 31 December 2021
Firmenich annual report for the financial year ended 2021
Firmenich interim consolidated financial statements for the six months ended 31 December 2020
Firmenich annual report for the financial year ended 2020
DSM Q3 2022 trading update
DSM HY 2022 financial statements & auditor's report
22.11.2022
DSM consolidated financial statements for the financial years ended 31 December 2021 and 2020 & auditor’s report
22.11.2022
DSM integrated annual report 2021
DSM integrated annual report 2020
DSM integrated annual report 2019
EGM voting results
23.01.2023
EGM minutes
23.01.2023
Position statement
Convocation notice, agenda & notes
22.11.2022
Form B - proxy
Form A - notification
22.11.2022
DSM virtual meeting manual & FAQ
22.11.2022
Form C - voting instructions
Proposed amendment to the Articles of Association for the conversion of DSM N.V. into DSM B.V.
DSM's policy regarding hybrid shareholder meetings
Merger proposal
Merger proposal: Schedule A
Merger proposal: Schedule B
Merger proposal: Schedule C
Merger proposal: Schedule D (Auditor's report)
22.11.2022
Merger Proposal: Explanatory notes
22.11.2022
Explanatory Notes: Schedule (Auditor’s assurance report)
Whether you’re a shareholder, potential shareholder, or analyst, our Investor relations team is on hand to answer your questions.
Two global leaders in science and innovation have joined forces to become dsm-firmenich, creating a world of potential for investors.
Tools to track your share performance.